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Various human metal intoxications have been
treated efficiently by administration of a
chelating agent. However, complexation reac-
tions in the human body are inﬂuenced by a
multitude of factors, including competing
metals and ligands, dynamics of circulation,
compartmentalization, and metabolism of the
chelating agent. Accordingly, in vivo chelation
reactions may differ extensively from what
would be expected from our chemical knowl-
edge about the metal and the chelating agent.
Chelating agents can affect metal toxicity by
mobilizing the toxic metal into (mainly) urine.
However, an important effect of chelation is
reduction of metal toxicity. A chelating agent
forming a stable complex with a toxic metal
may shield biological targets from the metal
ion, thereby reducing the local toxicity (1,2),
even at times after administration when mobi-
lization has not yet occurred, or it may expose
the metal to the biological environment and
thereby increase the toxicity of the metal. For
example, desferrioxamine (DFOA) completely
covers the surface of Fe3+ during complex for-
mation, thereby preventing iron-catalyzed free
radical reactions (3,4); however, ethylenedi-
amine-tetraacetic acid (EDTA) is not able to
shield the surface of the Fe3+ ion but forms an
open complex (“basket complex”), thereby
increasing the catalytic capacity of Fe3+ for
generating oxidative stress by about one order
of magnitude (5).
The oral use of chelating agents is generally
considered to require that further exposure to
the metal cease in order to avoid chelator-
mediated increased intestinal metal absorption.
However, orally administered chelating agents
forming hydrophilic metal complexes may efﬁ-
ciently reduce intestinal metal uptake and local
toxicity at early times after oral intoxication.
This was shown for the diethylenetriamine
pentaacetic acid (DTPA) complex of Cd2+ (6).
Also orally administered dimercaptosuccinic
acid (DMSA) reduced the intestinal uptake and
toxicity of oral Cd2+ (2). Chelation of Ni2+
with EDTA and Hg2+ with DMSA or dimer-
captopropionic sulfonate (DMPS) (7) reduced
intestinal uptake. Accordingly, oral administra-
tion of chelating agents may in some cases offer
both reduction of local toxicity and prevention
of intestinal metal uptake (1,2,8).
Thermodynamic
Considerations
In simple cases of formation of metal com-
plexes with polydentate ligands, M + Li
→ MLi, where M represents the solvated elec-
tron pair–accepting metal ion and Li repre-
sents a chelator with i electron-pair–donating
ligands (Lewis bases and acids), the overall
stability constants is
[1]
The stability of this complex depends on ∆ G
= ∆ H – T ∆ S = RT lnβ i. For a complex with
i ligands not associated in one molecule, the
change in enthalpy related to bonding often
contributes considerably to the free energy
because the unfavorable entropy change asso-
ciated with ordering i independent ligands
around one ion counteracts the entropy effect
of desolvation of the groups. Accordingly,
multidentate ligands form more stable com-
plexes than unidentate ligands because of the
fully available entropy contribution from des-
olvation, and the stability in general increases
with the number of rings formed. If one
assumes that the enthalpy change due to
complex formation does not depend on
whether the donor groups are independent or
joined in a multidentate ligand (which is not
always true, however), the chelate effect
should be entirely due to the entropy change.
The entropy contribution is indeed often the
primary determinant of increased stability of
metal complexes with multidentate ligands,
but when mutual repulsive forces between
charged groups are overcome by introducing
them into one molecule, a considerable
enthalpy effect may result. This may be illus-
trated by the thermodynamics of iminodi-
acetic acid (IDA) and EDTA complex
formation with Cd2+ (Table 1, Figure 1).
Even though the two complexes have the
same number of groups (six) available for
chelation, the number of rings is increased by
one in the EDTA complex, increasing the
entropy contribution to stability. Further,
assembling the four negatively charged car-
boxyl groups in EDTA increases the enthalpy
contribution. It can easily be calculated that
the two contributions are of similar size.
The size of the chelate effect can be visual-
ized from the change in log β for complexes
with multidentate ligands with increasing
numbers of identical donor groups. Thus, the
stability of the Cd complexes with the
polyaminopolycarboxylic acids increases in the
following series: IDA with three donor groups
and log β = 5.71; nitrilotriacetic acid with
four donor groups and log β = 9.78; EDTA
with six donor groups and log β = 16.36; and
β i
i
i
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DTPA with eight donor groups and log β =
19.00 (9). Similar effects are seen with the
series of homologous polyamines, where log β
for the Cd complexes increases from 5.45 to
16.10 when the number of donors increases
from two to five (9). Steric conditions (e.g.
ion size and ring size) considerably inﬂuence
the stability, mainly through changes in ∆ H.
Hardness/Softness of 
Metal Ions and Ligands
Determining factors for complex stability are
the hardness/softness (HS) characteristics of
electron donors and acceptors, discussed in
the classical work by Schwarzenbach (10) and
Ahrland et al. (11) and further elaborated into
the hard and soft acids and bases (HSAB)
concept by Pearson (12). The HS characteris-
tics of donor and acceptor atoms in complexa-
tion reactions determine not only stability of
the formed complex but also the chelator’s
degree of metal selectivity in relation to com-
peting essential metals present in biological
ﬂuids. Further, the HS character determines
the selectivity of the toxic metal for the chela-
tor in relation to the competing biological lig-
ands, often available at high concentrations
compared with that of the chelating agent.
Softness character is related to the ability of
the empty frontier orbital of metal ions to
accept electrons and to the deformability of
the outermost occupied electron orbital of
donor groups—that is, the propensity of met-
als and donors for forming covalent bonds.
The ionic index, Z2/r, where Z and r are the
ion’s charge and radius, respectively, is posi-
tively related to degree of ionic bonding in an
ion’s complexes. Conversely, the softness of an
ion increases with the size of sum of the ion-
ization energies divided by the ionic index
(13), rI/Z2. Nieboer and Richardson (14)
described softness by the covalent index, Xm
2r,
where Xm is the electronegativity. The ratio-
nale is that Xm is related to the ion’s empty
frontier orbital energy and thereby to the ion’s
ability to accept electrons and form covalent
bonds. In brief, metal ions and donor groups
prefer to form complexes with partners having
similar HS character; however, the stability of
complexes increases with the softness of both
metal and donor. Thus, for a series of cad-
mium complexes with simple tridentate lig-
ands, made by substituting the imino H in
IDA with different functional groups, log β
increases from 5.71 (R = H) or 6.75 (R =
CH3)to 9.78 (R = COO–), 10.53 (R = NH2),
or even 16.72 (R = SH) (9):
RN(COO–) + Cd2+ → Cd2+RN(COO–). [2]
For another series of complexes, log β  varies
between 12.43 (R = CH3) and 22.33 
(R = SH) (9):
2RN(COO–)2 + Cd2+ → Cd2+[RN(COO–)2]2.
[3]
Competition, Rate Effects 
during Ligand Exchange, 
and Toxicokinetics
The concentrations of “free” toxic metals
are often very low in biological systems
because of the availability of numerous
small biological ligands forming mixed
aquo-bioligand complexes with metals.
Therefore, complexation reactions in vivo
between toxic metals and “therapeutic”
chelating agents most often occur as a series
of ligand and/or metal exchange reactions.
Even if the equilibrium constant is highly
favorable, complex formation in vivo may
be limited because of rate effects, competi-
tion by other ligands/metals, and systemic
transport kinetics of the chelator. Under
physiological conditions, numerous small
mono- and bidentate ligands as well as
functional groups in proteins participate in
chelation reactions and compete for chelat-
ing agents. Ca2+, present at a concentration
of about 1 mM, is the most important
metal species competing for clinical chelat-
ing agents. Anticipating that equilibrium is
achieved, and that the ML complex is quan-
titatively excreted in urine, the efficiency, E,
of a chelating agent for mobilizing a toxic
metal can be described as
[4]
because the potential for mobilizing the metal
depends on the degree of formation of the
ML complex. In the simple situation of one
major biological competing metal, Ca2+, and
a total chelator concentration Lt, the condi-
tions for a large E can be visualized from the
standard stability constants:
[5]
By introducing the stability constants for the
metal and calcium complexes into this expres-
sion and defining the concentration of Lt as
the sum of all forms of the chelator in plasma,
Schubert (15) derived
[6]
The mechanisms and kinetics of ligand
exchange reactions have been extensively
reviewed by Margerum et al. (16). They
supply data for a range of divalent ions, that
the rates of both solvent exchange and lig-
and exchange are related to the HS character
of electron donors and acceptors. The rate of
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Table 1. Thermodynamics of complex formation of
Cd with IDA and EDTA. 
Chelator Complex log K ∆ H ∆ S
IDA CdL2 1,019 –55 29
EDTA CdL 1,646 –91 44
Data from Martell and Smith (9).
DFOA
H2N
2
O O
CH3 N
OH
N
OH
NH
H2N
NH2
TETA
NH
NH
DPA
CH3
H3C
SH
NH2
OH
O
IDA
HOOC
HOOC
H N
EDTA
HOOC
HOOC
COOH
COOH
N
N
BAL
OH
HS
HS
DMPS
SO3H
HS
HS
O
OH
OH
HS
HS
O
DMSA
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complex formation depends on whether the
chelator can easily get a grip on the metal
ion by displacing a solvent molecule or a
monodentate ligand to obtain the initial
coordination site. The nature of this ligand
exchange reaction determines whether the
formed mixed complex is more or less stable
than the disrupted complex. If a more stable
complex is formed, further ligand exchange
reactions are thermodynamically facilitated,
sometimes even when subsequent ring open-
ing is involved. The next step is formation
of the first ring by coordinating a second
donor group of the multidentate ligand to
the metal ion, whereby the chelate effect
decreases the rate of dissociation of the com-
plex. Such processes may occur at a reason-
able speed. If the initial complexation
reaction involves breaking a preexisting
chelate ring formed with a biological multi-
dentate ligand, the process is often much
slower. Besides the number of donor groups
available for electron pair donation, that is,
the maximum number of rings formed con-
tributing to the chelate effect (the HS char-
acter of these donors), steric conditions for
simultaneous access of ligands to coordina-
tion positions on the metal ion determine
formation rate and overall stability.
Also, lipophilicity, metabolic stability, and
rate of (most often urinary) clearance are
important.
Because of the complexity of biological
systems, effects of antidotal chelators are
often better described quantitatively from
results of animal experiments or clinical
treatments than by theoretical calculations
of, for example, E. Increased mobilization of
the toxic metal in experimental animals or
humans, most often evaluated from urinary
output, and decreased mortality or toxicity
among exposed animals are major end
points. The mobilizing effectiveness (ME) is
expressed either as the factorial increase MEF
in urinary and fecal excretion between
treated and un- or pretreated animals or
humans, or as the fractional retention MEQ
of the metal in organs of treated animals rela-
tive to controls (17). The therapeutic effec-
tiveness (TE) may be expressed for acute
metal intoxication by the factorial change
TEF in LD50 (the dose killing 50% of
exposed animals) due to the chelation treat-
ment (17). Similarly, two chelators may be
compared from results of animal experiments
by their relative potency, which is the ratio
between equally effective doses, or by their
relative efﬁciency (RE) the ratio of effects at
equimolar doses (17). Because the efficiency
of different chelators toward acute metal tox-
icity may vary extensively in some combina-
tions allowing 100% survival even after doses
considerably higher than LD99 (1,2), the RE
method has limited applicability.
New Paradigms in Clinical
Chelation Treatment: 
The Exit of BAL
EDTA,  D-penicillamine, and British
antilewisite [2,3-dimercaptopropanol (BAL)]
came into clinical use after World War II to
treat lead and mercury intoxication, and cop-
per intoxication in Wilson disease (18),
which is today treated with triethylene-
tetramine (19,20). In 1962, DFOA was
shown to increase urinary iron excretion in
patients with thalassemia (21). Today, DFOA
is also used to treat aluminum intoxication
and iron storage toxicity in sickle cell anemia
patients. During the 1950s DMSA and
DMPS came into use in China (22–24) and
the Soviet Union (25,26). Since the 1970s
these drugs have been available as experimen-
tal drugs in the Western countries. DMSA
and DMPS are efﬁcient antidotes for intoxi-
cations with several divalent metals besides
lead and mercury as well as some organometal
or metalloid compounds (8,27). Both chela-
tors are available as tablets for oral adminis-
tration, which are stable for long periods at
room temperature, and DMPS also as a dry
preparation for parenteral administration
after hydration. In China, DMSA has been
administered parenterally to hundreds of
patients (22). BAL is unstable, susceptible to
oxidation, and difﬁcult to store as a ready-for-
use preparation. It has a low therapeutic efﬁ-
cacy in most cases, and because of high
toxicity, BAL is suited only for brief treat-
ment of acute intoxications. It can be admin-
istered only by intramuscular injection,
normally in peanut oil. Administration of
local anesthesia beforehand is necessary
because the injection is very painful. Presently
available experience indicates that DMSA or
DMPS can substitute for BAL in most clini-
cal situations, resulting in safer and more
efﬁcacious treatment.
Side Effects and Toxicity 
of BAL, DMSA, and DMPS
A considerable fraction of individuals treated
with BAL experience unpleasant side effects,
including nausea, vomiting, sweating, high
fever, hypertension, and tachycardia. BAL
administration increased the brain deposition
of arsenite (28) and organic mercury com-
pounds (29) and increased the toxicity of
cadmium (30) and lead (31) in animal experi-
ments. DMPS does not redistribute arsenic,
lead, or inorganic mercury to the brain
(28,32), and DMSA chelation decreases the
brain deposition of lead (33) and methylmer-
cury (34). BAL is signiﬁcantly more toxic than
DMPS, which is slightly more toxic than
DMSA. Representative LD50 values selected
from the large number of published toxicity
studies are are given in Table 2.
In the only reported case of a DMSA over-
dose, a 3-year-old girl ingested approximately
2.4 g DMSA or 185 mg/kg body weight with-
out clinical signs of intoxication (40). During
the last two decades, many patients have been
treated with DMSA in the United States and
with DMPS in Europe, with a very low fre-
quency of toxic side effects necessitating dis-
continued treatment. Adverse reactions during
treatment with DMSA or DMPS include gas-
trointestinal discomfort, skin reactions, mild
neutropenia, and elevated liver enzymes. For
both compounds, symptoms may subside,
allowing continued therapy. DMPS seems to
be better tolerated than is DMSA with respect
to gastrointestinal symptoms but may cause
hypotension, especially after rapid intravenous
infusion. Some patients, especially those with
allergic asthma symptoms, may develop hyper-
sensitivity to DMPS (41,42).
For DMSA two serious reactions to
therapy have been reported: DMSA chelation
of a man with chronic lead intoxication was
discontinued because of a strong mucucuta-
neous reaction to the drug (43). A 45-year-old
African-American man developed hemolytic
anemia during DMSA chelation for occupa-
tional lead intoxication. After cessation of
treatment, the hematological values normal-
ized. The patient was glucose 6-phosphate
dehydrogenase deﬁcient, a genetic trait known
to contraindicate BAL chelation because of
risk of hemolysis (44). For DMPS, severe tox-
icity has not been reported in peer-reviewed
literature except for a case of Stevens-Johnson
syndrome in a lead-intoxicated patient after
eight daily oral doses of 200 mg/m2 DMPS
(45). DMSA is registered in the United States
as a drug for treatment of lead intoxication.
DMPS is registered in Germany for treatment
of mercury intoxication; however, it is not
approved in the United States, so unless spe-
cial permission is given by the U.S. Food and
Drug Administration, it is not lawful for
physicians to use it in the United States, nor is
it lawful for pharmacies to compound it. Still,
DMPS is being illegally used by members of
the alternative health industry to treat people
allegedly suffering from mercury intoxication,
most often claimed to be due to amalgam
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Table 2. Representative LD50 values for clinically relevant dimercapto chelating compounds.
Compound Species Administration route LD50  Reference
BAL Mouse Intraperitoneally 90–180 mg/kg (35,36)
DMSA Mouse Orallly 4.34 g/kg (37)
DMSA Mouse Intraperitoneally 2.48 g/kg (38)
DMPS Mouse, rat Intraperitoneally 1.1–1.4 g/kg (28,39)ﬁllings. Similar uses occur in European coun-
tries. Anecdotal information suggests that a
very low fraction of individuals develops
severe reactions after parenteral administration
of DMPS.
Conclusions and Directions 
of Future Studies
During the last 15 years DMSA and DMPS
have gained more general acceptance among
clinicians, undoubtedly improving the man-
agement of many human metal intoxications.
Still, knowledge is needed in several basic
research areas of in vivo chelation of metals,
for example,
• molecular mechanisms of action of clinically
important chelators
• intracellular and extracellular chelation in
relation to mobilization of aged metal
deposits and the possible redistribution of
toxic metal to sensitive organs such as the
brain
• effects of chelators on metal biokinetics dur-
ing continued exposure to the metal, espe-
cially possible enhancement or reduction of
intestinal metal uptake
• combined chelation treatment with
lipophilic and hydrophilic chelators, which
presently has a minimal clinical role
• minimization of the mobilization of essential
trace elements during long-term chelation
• fetotoxic and teratogenic effects of chelators
• development of orally administrable chelators
• development of less toxic chelators for
chronic treatment of genetic metal storage
diseases
Especially the two last points, continued
development of orally administrable chelating
agents for efﬁcient, nontoxic mobilization on
a home-patient basis over extended time peri-
ods (even life-long chelation) of aged deposits
of toxic metal (e.g., Al, Cd, Fe, Hg, and Cu)
will probably be a main future research issue.
Also, extensive animal experiments compar-
ing the efficacies of classical chelators (espe-
cially BAL) with those of DMSA and DMPS
in acute intoxications using relevant exposure
routes (i.e., oral administration of relevant
species of the metals, as well as inhalation of
Hg vapor) is a prerequisite for phasing out
the old chelators in uses where more effective
alternatives are now available.
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